



VOLUME SEVENTY FIVE

ADVANCES IN INORGANIC CHEMISTRY

Medicinal Chemistry

Edited by

PETER J. SADLER

*University of Warwick
Coventry, United Kingdom*

RUDI van ELDIK

*University of Erlangen–Nuremberg, Germany
Jagiellonian University, Krakow, Poland
N. Copernicus University, Torun, Poland*



ELSEVIER



ACADEMIC PRESS

An imprint of Elsevier

Contents

| | |
|---------------------|-----------|
| <i>Contributors</i> | <i>xi</i> |
| <i>Preface</i> | <i>xv</i> |

Feature Article

| | |
|---|-----------|
| 1. 150 years of the periodic table: New medicines and diagnostic agents | 3 |
| Cinzia Imberti and Peter J. Sadler | |
| 1. Introduction | 4 |
| 2. Transferrin: Transport and delivery of iron and metallodrugs | 17 |
| 3. Metal complexes as imaging probes | 21 |
| 4. Design of metallodrugs | 31 |
| 5. Conclusions and future outlook | 43 |
| Acknowledgments | 46 |
| References | 46 |
| 2. Medicinal inorganic chemistry: New perspectives and targets for the periodic table | 57 |
| Nicholas P. Farrell | |
| 1. Introduction | 58 |
| 2. The polynuclear platinum concept | 61 |
| 3. The extracellular matrix and bioinorganic chemistry | 66 |
| 4. The role of endogenous metal ions and metal complexes in angiogenesis and metastasis | 80 |
| 5. Conclusions and future perspectives | 82 |
| Acknowledgements | 83 |
| References | 83 |
| 3. Anti-cancer gold, platinum and iridium compounds with porphyrin and/or N-heterocyclic carbene ligand(s) | 87 |
| Ka-Chung Tong, Di Hu, Pui-Ki Wan, Chun-Nam Lok, and Chi-Ming Che | |
| 1. Introduction | 88 |
| 2. Stable anti-cancer metal complexes with porphyrin and/or N-heterocyclic carbene (NHC) ligand(s) | 89 |

| | |
|--|------------|
| 3. Metal complexes with NHC ligands | 97 |
| 4. Conclusions and future perspectives | 117 |
| Acknowledgment | 117 |
| References | 118 |
| 4. Metal <i>N</i>-heterocyclic carbene complexes in medicinal chemistry | 121 |
| Ingo Ott | |
| 1. Introduction | 122 |
| 2. Ruthenium NHC complexes | 123 |
| 3. Rhodium NHC complexes | 126 |
| 4. Silver NHC complexes | 129 |
| 5. Iridium NHC complexes | 132 |
| 6. Gold NHC complexes | 135 |
| 7. Summary and future perspectives | 143 |
| References | 144 |
| 5. Rational design of anticancer platinum(IV) prodrugs | 149 |
| Shuren Zhang, Xiaoyong Wang, and Zijian Guo | |
| 1. Introduction | 150 |
| 2. Pt ^{IV} complexes for overcoming cisplatin resistance | 152 |
| 3. Pt ^{IV} complexes for reducing systemic toxicities | 168 |
| 4. Pt ^{IV} complexes targeting tumor microenvironment | 172 |
| 5. Conclusions and perspectives | 177 |
| Acknowledgments | 178 |
| References | 178 |
| 6. Bismuth drugs as antimicrobial agents | 183 |
| Runming Wang, Hongyan Li, Tiffany Ka-Yan Ip, and Hongzhe Sun | |
| 1. Introduction | 184 |
| 2. Antimicrobial activities of bismuth drugs against <i>H. pylori</i> | 185 |
| 3. Potential bismuth-based agents in development | 194 |
| 4. Conclusion and perspectives | 199 |
| Acknowledgments | 200 |
| References | 200 |
| 7. Antimony and bismuth as antimicrobial agents | 207 |
| Rebekah N. Duffin, Melissa V. Werrett, and Philip C. Andrews | |
| 1. Introduction | 208 |
| 2. Synthetic strategies for antimony and bismuth complexes | 209 |

| | |
|---|------------|
| 3. Bismuth and antimony as anti-leishmanials | 212 |
| 4. Bismuth as an antibacterial | 230 |
| 5. Conclusions and future perspectives | 249 |
| Acknowledgments | 250 |
| References | 251 |
| 8. Pharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes | 257 |
| Yao Zhao, Yankang Yang, Fengmin Xu, Wei Zheng, Qun Luo, Yanyan Zhang, Feifei Jia, and Fuyi Wang | |
| 1. Introduction | 258 |
| 2. Multi-targeting metal-based anticancer complexes | 261 |
| 3. Conclusion and future prospects | 279 |
| Acknowledgments | 280 |
| References | 280 |
| 9. Organelle-targeting metal anticancer agents | 287 |
| Lina Xie, Ruilin Guan, Thomas W. Rees, and Hui Chao | |
| 1. Introduction | 288 |
| 2. Detecting the localization of therapeutic agents in cells | 290 |
| 3. Mitochondria | 290 |
| 4. Lysosomes | 304 |
| 5. The nucleus | 309 |
| 6. The endoplasmic reticulum | 316 |
| 7. Cytoplasmic membrane | 322 |
| 8. Perspective on organelle-targeting metal anticancer agents | 329 |
| Acknowledgments | 330 |
| References | 330 |
| Further reading | 337 |
| 10. From the hypothesis-driven development of organometallic anticancer drugs to new methods in mode of action studies | 339 |
| Muhammad Hanif and Christian G. Hartinger | |
| 1. Introduction | 339 |
| 2. Organometallic scaffolds in anticancer agents | 340 |
| 3. Novel bioanalytical methods for mode of action studies | 350 |
| 4. Conclusions and future perspectives | 353 |
| Acknowledgments | 355 |
| References | 355 |

| | |
|---|------------|
| 11. Design and applications of catalytic metallodrugs containing the ATCUN motif | 361 |
| Zhen Yu and James A. Cowan | |
| 1. Introduction | 362 |
| 2. Catalytic metallodrugs targeting G-quadruplex telomeric DNA as anticancer agents | 365 |
| 3. Metallopeptides targeting L-fucose of H-antigen on the surface of red blood cells | 370 |
| 4. Catalytic metallodrugs targeting Flavivirus NS2B/NS3 proteases | 376 |
| 5. Antimicrobial peptides targeting bacterial membranes | 382 |
| 6. Conclusions and future scope for use of the ATCUN motif in medicinal chemistry | 387 |
| Acknowledgments | 388 |
| References | 388 |
| | |
| 12. The eyes have it: Using X-ray crystallography to determine the binding modes of medically relevant ruthenium/DNA complexes | 393 |
| Kane T. McQuaid and Christine J. Cardin | |
| 1. Introduction | 394 |
| 2. Structural studies of ruthenium polypyridyl complexes with nucleic acids | 399 |
| 3. Seeing G-quadruplex binding | 408 |
| 4. Seeing the effect of structure on luminescence properties | 418 |
| 5. Overview and outlook | 420 |
| Acknowledgments | 421 |
| References | 421 |
| | |
| 13. Interaction of metal complexes with G-quadruplex DNA | 425 |
| Ramon Vilar | |
| 1. Introduction | 425 |
| 2. Biological roles of G-quadruplexes | 427 |
| 3. Mono-metallic complexes as G4 DNA binders | 430 |
| 4. Di-metallic complexes as G4 DNA binders | 438 |
| 5. Concluding remarks and future perspectives | 442 |
| References | 443 |

| | |
|---|----------------|
| 14. CXCR4-targeted metal complexes for molecular imaging | 447 |
| Isaline Renard and Stephen J. Archibald | |
| 1. Introduction | 448 |
| 2. The chemokine receptor CXCR4 | 449 |
| 3. CXCR4 binding moieties: Azamacrocycles and peptides | 452 |
| 4. CXCR4 targeted positron emission tomography imaging probes | 459 |
| 5. Conclusions and future perspectives | 470 |
| Acknowledgments | 472 |
| References | 472 |
| <i>Index</i> | 477 |